San Diego, 6/14/23 - Grann Pharmaceuticals Inc., a biotechnology company specializing in innovative treatments for neurodegenerative diseases, is proud to announce the successful closing of a seed funding round, raising $750,000. The funding will be utilized to accelerate the development of a groundbreaking therapeutic using RNA-based treatments for patients affected by Alzheimer's disease.
The funds raised will be allocated towards expanding the company's research and development capabilities, strengthening its scientific team, and conducting rigorous preclinical studies. Grann Pharmaceuticals Inc. aims to leverage RNA-based treatments, which have demonstrated tremendous potential in targeting the underlying causes of Alzheimer's disease and modifying disease progression.
"We are thrilled to have secured this significant seed funding, as it represents a crucial step forward in our mission to develop effective therapies for patients suffering from Alzheimer's disease," said Thomas Lyle Temple, President & CEO of Grann Pharmaceuticals Inc. "This funding will allow us to accelerate our research efforts and bring us closer to providing a transformative treatment option for those afflicted by this devastating disease."
Grann Pharmaceuticals' innovative approach is leveraging RNA lipid nanoparticle-based treatments to target specific disease-related proteins and modulate their expression levels. By doing so, the company aims to halt or reverse the neurodegenerative processes associated with Alzheimer's disease, providing hope for improved patient outcomes and enhanced quality of life.
Grann Pharmaceuticals extends its sincere appreciation to its investors for their unwavering support and confidence in the company's vision and potential. Moving forward, Grann Pharmaceuticals remains dedicated to advancing the development of its RNA-based therapeutic and aims to initiate clinical trials in the near future. The company's commitment to innovation and patient-centric research positions it as a leading force in the fight against Alzheimer's disease.
For media inquiries, please contact:
Patrick Granahan
Business Development
(760) 805-3663
Patrickg@grannpharma.com
Comments